This noninvasive peripheral blood analysis coupled with a rapid flow cytometry protocol the same day after drawing could help to refine decision-making on ICIs in the clinical setting, which currently relies on the PD-L1 protein expression in tumor tissue in advanced NSCLC patients. Here, CD274 is linked to neoplasm.